Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

• Published in: American journal of clinical dermatology 2024-03, Vol.25 (2), p.299-314
• Main Authors: King, Brett, Soung, Jennifer, Tziotzios, Christos, Rudnicka, Lidia, Joly, Pascal, Gooderham, Melinda, Sinclair, Rodney, Mesinkovska, Natasha A., Paul, Carle, Gong, Yankun, Anway, Susan D., Tran, Helen, Wolk, Robert, Zwillich, Samuel H., Lejeune, Alexandre
• Format: Article
• Language: English
• Subjects: Alopecia; Baldness; Cancer therapies; Dermatology; Hair loss; Medicine; Medicine & Public Health; NCT; NCT02974868; NCT03732807; NCT04006457; NCT04517864; Original; Original Research Article; Patients; Pharmacology/Toxicology; Pharmacotherapy; Skin cancer
• ISSN: 1175-0561; 1179-1888; 1179-1888
• DOI: 10.1007/s40257-024-00846-3

Background The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). Objective The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. Methods Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort. Proportions and study size–adjusted incidence rates (IRs) of adverse events (AEs) of interest and laboratory abnormalities are reported. Results In the placebo-controlled cohort ( n = 881; median exposure: 169 days), the proportion of ritlecitinib-treated patients with AEs was 70.2–75.4% across doses versus 69.5% in the placebo group; serious AEs occurred in 0-3.2% versus 1.9% for the placebo. A total of 19 patients permanently discontinued due to AEs (5 while receiving the placebo). In the all-exposure cohort ( n = 1294), median ritlecitinib exposure was 624 days [2091.7 total patient-years (PY)]. AEs were reported in 1094 patients (84.5%) and serious AEs in 57 (4.4%); 78 (6.0%) permanently discontinued due to AEs. The most common AEs were headache (17.7%; 11.9/100 PY), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (15.5%; 9.8/100 PY), and nasopharyngitis (12.4%; 8.2/100 PY). There were two deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest). Proportions (IRs) were < 0.1% (0.05/100 PY) for opportunistic infections, 1.5% (0.9/100 PY) for herpes zoster, 0.5% (0.3/100 PY) for malignancies (excluding nonmelanoma skin cancer), and 0.2% (0.1/100 PY) for major adverse cardiovascular events. Conclusions Ritlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available). Trial Registries ClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019).